PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-224315.95%
Negative net income growth while CRVO stands at 279.00%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
418.75%
Some D&A expansion while CRVO is negative at -55.05%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
2984.50%
SBC growth of 2984.50% while CRVO is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
29070.41%
Well above CRVO's 88.51% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5571250.00%
AP growth well above CRVO's 385.23%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
12125.42%
Growth well above CRVO's 2305.86%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
753.88%
Some yoy increase while CRVO is negative at -4262.86%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-298628.16%
Both yoy CFO lines are negative, with CRVO at -167.75%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-260.15%
Negative yoy CapEx while CRVO is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-260.15%
We reduce yoy invests while CRVO stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.